Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation ( IART ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the Integra LifeSciences Third Quarter 2025 Financial Results. [Operator Instructions] As a reminder, this call may be recorded.
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mojdeh Poul CEO | NASDAQ (NGS) Exchange | 457985208 CUSIP |
| US Country | 4,396 Employees | - Last Dividend | 1 Jul 2015 Last Split | 16 Aug 1995 IPO Date |
Founded in 1989 and headquartered in Princeton, New Jersey, Integra LifeSciences Holdings Corporation stands as a pioneering entity in the medical device industry. The company thrives on manufacturing and marketing an array of surgical instruments, neurosurgical products, and advanced wound care products that cater to specialized fields like neurosurgery, neurocritical care, and otolaryngology. Integra LifeSciences operates through two primary divisions: Codman Specialty Surgical and Tissue Technologies. These divisions underscore the company’s commitment to innovation, quality, and patient care by offering cutting-edge products and services that address critical needs across various healthcare settings. By maintaining a direct sales force and a network of distribution channels, Integra LifeSciences ensures its offerings are accessible to hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, as well as dental, podiatry, and veterinary practices across the United States, Europe, Asia Pacific, and other international markets.
Integra offers a comprehensive range of products for neurosurgery and neurocritical care, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. These products are essential for surgeries and treatments related to the brain, spinal cord, and other components of the nervous system, seeking to improve patient outcomes through precision and reliability.
The company also specializes in high-quality surgical instruments and surgical headlamps, designed to aid in various surgical procedures across specialties. Coupled with an array of after-market services, these products ensure clinicians have access to durable, precise tools for a plethora of medical procedures, enhancing operative efficiency and patient safety.
Focused on the healing of acute wounds, Integra’s regenerative technology products span advanced solutions that promote the body's natural healing processes. These products are instrumental in treating complex wounds, driving faster recovery times, and improving the quality of life for patients enduring acute wound challenges.
Addressing needs in hernia, tendon, and peripheral nerve repair and protection, Integra's surgical tissue repair products are at the forefront of surgical innovation. These offerings leverage the latest advancements in medical technology to provide effective, minimally invasive solutions for tissue repair, aiding in the restoration of function and preventing further injury.
Integra's portfolio also includes products for skin and wound repair, alongside solutions for plastics and surgical reconstruction. Whether it's bone grafts or nerve and tendon repair products, the company delivers a broad spectrum of materials and technologies designed to aid in the repair, reconstruction, and enhancement of patient structural integrity and function post-surgery or injury.